Trial Profile
A Phase II, Multicenter, Randomized, Open-Label, Dose-Ranging, Parallel Group Study to Compare the Anti-Viral Effects, Pharmacokinetics and Safety of HepeX-B, a Mixture of Two Monoclonal Antibodies, as Compared to Hepatitis B Immune Globulin in Patients Who Have Received Hepatic Allografts for Treatment of End-Stage Liver Disease Due to Hepatitis B Virus Infection
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs XTL 001 (Primary) ; Hepatitis B immune globulin
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Cubist Pharmaceuticals; XTL Biopharmaceuticals
- 15 Nov 2019 According to EudraCT record this trial has been completed in UK location ( date of global end of the trial 2005-08-30)
- 31 Oct 2005 New trial record.